| Target and Pathway |
Top |
| Target(s) |
Histone deacetylase 1 (HDAC1) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 10 (HDAC10) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 11 (HDAC11) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 2 (HDAC2) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 3 (HDAC3) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 4 (HDAC4) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 5 (HDAC5) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 6 (HDAC6) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 7 (HDAC7) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 8 (HDAC8) |
Target Info
|
Inhibitor |
[1] |
| Histone deacetylase 9 (HDAC9) |
Target Info
|
Inhibitor |
[1] |
| Target's Patent Info |
Histone deacetylase 1 (HDAC1) |
Target's Patent Info
|
[1] |
| Histone deacetylase 10 (HDAC10) |
Target's Patent Info
|
[1] |
| Histone deacetylase 11 (HDAC11) |
Target's Patent Info
|
[1] |
| Histone deacetylase 2 (HDAC2) |
Target's Patent Info
|
[1] |
| Histone deacetylase 3 (HDAC3) |
Target's Patent Info
|
[1] |
| Histone deacetylase 4 (HDAC4) |
Target's Patent Info
|
[1] |
| Histone deacetylase 5 (HDAC5) |
Target's Patent Info
|
[1] |
| Histone deacetylase 6 (HDAC6) |
Target's Patent Info
|
[1] |
| Histone deacetylase 7 (HDAC7) |
Target's Patent Info
|
[1] |
| Histone deacetylase 8 (HDAC8) |
Target's Patent Info
|
[1] |
| Histone deacetylase 9 (HDAC9) |
Target's Patent Info
|
[1] |
|
KEGG Pathway
|
Cell cycle
|
|
Notch signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Huntington's disease
|
|
Alcoholism
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Viral carcinogenesis
|
|
Chronic myeloid leukemia
|
|
MicroRNAs in cancer
|
|
Amphetamine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Panther Pathway
|
Wnt signaling pathway
|
|
p53 pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class I
|
|
Regulation of Telomerase
|
|
Glucocorticoid receptor regulatory network
|
|
Direct p53 effectors
|
|
Hedgehog signaling events mediated by Gli proteins
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Signaling events mediated by HDAC Class II
|
|
Signaling events mediated by HDAC Class III
|
|
Sumoylation by RanBP2 regulates transcriptional repression
|
|
Validated nuclear estrogen receptor alpha network
|
|
Retinoic acid receptors-mediated signaling
|
|
Validated targets of C-MYC transcriptional repression
|
|
Regulation of retinoblastoma protein
|
|
Notch signaling pathway
|
|
E2F transcription factor network
|
|
Presenilin action in Notch and Wnt signaling
|
|
Regulation of Androgen receptor activity
|
|
IL3-mediated signaling events
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
p75NTR negatively regulates cell cycle via SC1
|
|
NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
HDACs deacetylate histones
|
|
NoRC negatively regulates rRNA expression
|
|
RNA Polymerase I Transcription Initiation
|
|
Factors involved in megakaryocyte development and platelet production
|
|
G0 and Early G1
|
|
Formation of the beta-catenin:TCF transactivating complex
|
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
|
Deactivation of the beta-catenin transactivating complex
|
|
Assembly of the primary cilium
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Notch Signaling Pathway
|
|
Neural Crest Differentiation
|
|
Signalling by NGF
|
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell Cycle
|
|
Endochondral Ossification
|
|
Cardiac Hypertrophic Response
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
TarBasePathway
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
SIDS Susceptibility Pathways
|
|
TGF beta Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
|
Retinoblastoma (RB) in Cancer
|
|
TWEAK Signaling Pathway
|
|
Integrated Breast Cancer Pathway
|
|
Mitotic G1-G1/S phases
|
|
Androgen receptor signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Ectoderm Differentiation
|
